Larger NGS Gene Panel Linked to More Clinical Utility
Evaluation of the clinical utility of two different size next-generation sequencing gene panels in solid tumours showed a preference for a larger panel across all tumour types investigated
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1397 results
Triple Blockade Demonstrates High Response Rates in Metastatic Melanoma
Response was found to associate with specific biomarkers and biomarker modulations following treatment
The Nobel Prize in Chemistry 2020 was Awarded “for the Development of a Method for Genome Editing”
CRISPR/Cas9 system has had a revolutionary impact on the life sciences, contributing to development of new cancer therapies
Fragment Analysis Is a More Reliable MET Exon 14 Screening Strategy for Identifying Large Deletions
MET alterations may identify candidates for targeted therapy and signal decreased immunotherapy benefit in NSCLC
Patients with Early Stage NSCLC Have a Higher TMB in Comparison to Advanced Stage Disease
Tumour mutational burden and molecular signatures may indicate potential benefit from immunotherapy in early stage non-small cell lung cancer
Radiation-Induced ‘Genomic Scars’ Associate with Poor Patient Outcome
Findings from an analysis of mutational spectra following radiotherapy
EMA Reminds Physicians to Use Atezolizumab with Nab-paclitaxel for Treating TNBC
Advice follows the release of results from the IMpassion131 study
FDA Approves Nivolumab and Ipilimumab for Unresectable Malignant Pleural Mesothelioma
Evidence for efficacy is based on the results from the CheckMate-743 study
EMA Recommends Granting a Marketing Authorisation for the Medicinal Product Nyvepria
Biosimilar pegfilgrastim received a positive opinion for reducing the duration of neutropenia and the incidence of febrile neutropenia
EMA Recommends Granting a Marketing Authorisation for Melphalan
A new hybrid medicine is intended for the treatment of certain haematological and other cancers and as reduced intensity conditioning treatment prior to allo-HSCT in haematological diseases.
Adolescent and Young Adult Cancer Survivors Face More Co-morbidity in Later Life Than Counterparts in the General Population
Description of the incidence and risk of co-morbidities developing subsequent to cancer treatment aids in creating tailored survivorship care
EMA Recommends Extension of Indications for Niraparib
New indication concerns maintenance treatment of adults with advanced ovarian cancer who are in response following completion of first-line platinum-based chemotherapy